FLT3 and acute graft versus host disease: Regarding these promising results, we decided to investigate whether the antibody-induced GVHD prevention and retained anti-tumor effect can be translated into an Fms like tyrosine kinase 3 (FLT3, CD135) internal tandem duplication (ITD) positive acute myeloid leukemia (AML) C3H mouse model since acute GVHD affects 45–53% of AML patients carrying FLT3 mutations (30, 31).